[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anxiety-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anxiety-disorder":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,41,67,91,135,165,197,228,252,274,298,327,358,380,402],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100636864","identification-and-molecular-characterisation-of-urban-environmental-stress-patterns-affecting-mental-illness-100636864",false,"NCT07571226","Identification and Molecular Characterisation of Urban-environmental Stress Patterns Affecting Mental Illness","Inclusion Criteria:\n\n1. Diagnosis: The primary diagnosis meets the DSM-IV criteria for depressive disorder, generalized anxiety disorder, or alcohol use disorder, and comorbid conditions may be present;\n2. Patients with mental disorders aged 18-60 years, with a balanced gender ratio;\n3. Normal intelligence and ability to use a smartphone running the Android operating system;\n4. Willingness to wear a wristband equipped with physiological monitoring functions (such as heart rate and electrodermal activity), download the study application, and upload data during the study period;\n5. Participants with depression or generalized anxiety disorder who are taking medication must be on a single stable dose of a selective serotonin reuptake inhibitor (SSRI), specifically citalopram or escitalopram, and this medication regimen must have been maintained for at least 5 days. Participants with alcohol use disorder who are taking medication have no restriction on the type of drug, but the medication regimen should also have been maintained for at least 5 days. At baseline assessment, patients with depression or anxiety disorders should have a Hamilton Depression Rating Scale (HAMD-17) score \\>7 or a Hamilton Anxiety Rating Scale (HAMA-14) score \\>7.;\n6. Voluntary participation in this study and signing of informed consent;\n7. For patients with alcohol use disorder (AUD): AUD patients must have successfully completed alcohol withdrawal, confirmed by clinical standards or relevant healthcare professionals.\n\nInclusion Criteria for Healthy Control Group\n\n1. Healthy subjects aged 18-60 years, with a balanced gender ratio;\n2. Normal intelligence and ability to use a smartphone running the Android operating system;\n3. Willingness to wear a wristband equipped with physiological monitoring functions (such as heart rate and electrodermal activity), download the study application, and upload data during the study period;\n4. Voluntary participation in this study and signing of informed consent.\n\nExclusion Criteria:\n\n1. Currently taking opioid medications;\n2. Receiving any form of brain stimulation therapy within the past 1 month (including transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), or other similar treatments);\n3. Skin infection or severe skin damage on the wrist or upper limbs that may affect the normal use of monitoring devices;\n4. Recent use (within 30 days) of medications that may interfere with drug metabolism, such as strong CYP450 inhibitors\u002Finducers;\n5. Severe physical diseases (such as brain tumors or injuries) or special conditions (such as current pregnancy or lactation) that may affect the study protocol;\n6. HAMD-17 item 3 (suicide) \\>3 points (severe suicidal behavior);\n\nExclusion Criteria for Healthy Control Group\n\n1. Currently using benzodiazepines or opioid medications;\n2. Currently receiving any form of brain stimulation therapy (including transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), or other similar treatments);\n3. Skin infection or severe skin damage on the wrist or upper limbs that may affect the normal use of monitoring devices;\n4. Recent use (within 30 days) of medications that may interfere with drug metabolism, such as strong CYP450 inhibitors\u002Finducers, or not reaching steady-state drug concentration before the study;\n5. Severe physical diseases (such as brain tumors or injuries) or special conditions (such as current pregnancy or lactation) that may affect the study protocol.",true,"ALL","18 Years","60 Years",{"count":20,"type":21},680,"ESTIMATED","OBSERVATIONAL","Mental disorders have become a major contributor to the global burden of non-communicable diseases, with disability-adjusted life years (DALYs) attributable to these conditions continuing to rise. Although evidence suggests that environmental factors may account for up to 40% of the attributable risk for mental disorders such as major depressive disorder, anxiety disorders, and alcohol use disorder, the underlying mechanisms remain unclear, particularly regarding how dynamic environmental stress influences disease onset, progression, and relapse. Traditional research has primarily focused on individual-level psychosocial factors, including socioeconomic status and life events, while lacking real-time, multidimensional assessments of objective urban environmental stressors such as air pollution, noise exposure, and reduced green space.\n\nThis study proposes a prospective longitudinal cohort design based in real-world environments, enrolling both patients with mental disorders and healthy controls. Using wearable devices integrated with the \"'StreetMind'\" mobile application and wear the visible watch, we will continuously and dynamically collect multimodal data on environmental exposures and physiological responses in urban settings. These include photoplethysmography (PPG)-derived heart rate, oxygen saturation, physical activity, and gait parameters, as well as objective environmental indicators such as temperature, humidity, light intensity, and noise levels. At baseline, all participants will undergo standardized psychiatric assessments to characterize depressive, anxiety, and addictive conditions. Peripheral blood and urine samples will also be collected for subsequent molecular and multi-omics analyses.\n\nThe study aims to systematically evaluate the associations between urban environmental factors-including air pollution, noise exposure, and green space availability-and the risk of mental disorder relapse. Furthermore, it seeks to elucidate the potential mechanisms by which environmental stress affects mental health through neuroinflammation and alterations in brain circuitry. The findings are expected to provide novel insights for risk prediction, early intervention, and precision management of mental disorders.",[25,26,27],"Major Depressive Disorder (MDD)","Anxiety Disorder","Alcohol Use Disorder (AUD)","RECRUITING","2026-05-31",{"date":31,"type":32},"2026-06-03","ACTUAL",{"date":34,"type":32},"2026-04-10",{"date":36,"type":21},"2029-05-30",{"name":38,"class":39},"Huashan Hospital","OTHER",3,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100515280","adaptation-of-individual-dialectical-behavior-therapy-intervention-for-transdiagnostic-treatment-of-emotional-disorders-100515280","NCT05989451","Adaptation of Individual Dialectical Behavior Therapy Intervention for Transdiagnostic Treatment of Emotional Disorders","Adaptation of Individual Dialectical Behavior Therapy Intervention for Transdiagnostic Treatment of Emotional Disorders in Two Medical Centers: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Mandarin Chinese-language proficiency sufficient to complete the study questionnaire\n2. A current diagnosis of depressive or anxiety disorder as diagnosed from a SCAN interview\n\nExclusion Criteria:\n\n1. Intellectual disability\n2. Substance use disorder in the past three months\n3. Bipolar disorder\n4. Psychotic disorder\n5. Organic brain disorder\n6. Acute suicidality or a history of frequent or recent suicide attempts\n7. Recent (past six weeks) change in psychiatric medication or unwillingness to maintain a stable dosage of medication during study participation\n8. Had received five or more sessions of CBT in the past five years or was unwilling to stop concurrent psychotherapy for an emotional disorder\n9. Any mental or physical condition requiring hospital admission\n10. Another medical condition likely to prevent participation in the study\n\nAs we also aim for a naturalistic setting, we do not exclude patients who undergo a medication change during the trial if this is judged necessary or clinically important by the treating clinician. Instead, we include a question about this in the questionnaire to the referring\u002Ftreating clinician.","65 Years",{"count":50,"type":21},250,"INTERVENTIONAL",[53],"NA","Anxiety and depressive disorders, referred to as emotional disorders, have high rates of prevalence, recurrence, and functional impairment. Transdiagnostic psychotherapy targeting shared features of these disorders has recently emerged. Dialectical behavior therapy (DBT) for the transdiagnostic treatment of emotional disorders is a promising approach, as results of preliminary studies for use in a broad range of mental disorders are encouraging. Since there is a lack of research on transdiagnostic psychotherapy in Taiwan, the investigators thus propose this 3-year randomized controlled trial to test the efficacy of a modified DBT for the treatment of transdiagnostic emotional disorders and to further evaluate whether the efficacy of modified DBT differs in the specific emotional disorders. The investigators expect that patients with emotional disorders receiving modified DBT are more likely to improve clinical outcomes, functioning, and quality of life.",[26,56],"Depressive Disorder","2026-05-27",{"date":59,"type":32},"2026-05-29",{"date":61,"type":32},"2023-09-01",{"date":63,"type":21},"2026-10",{"name":65,"class":39},"Mackay Memorial Hospital",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":51,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":66},"100457087","phase-2-pharmaco-neuroimaging-studies-of-approachavoidance-behaviors-and-post-mortem-studies-pharmacological-manipulation-100457087","NCT05232032","Pharmaco-Neuroimaging Studies of Approach\u002FAvoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation","Pharmaco-Neuroimaging Studies of Approach\u002FAvoidance Behaviors and Post-Mortem Studies: Study 1.1. (Pharmacological Manipulation)","Inclusion criteria for MDD\u002Fanxiety disorder group:\n\n* DSM-5 diagnostic criteria for MDD, Generalized Anxiety Disorder, Social Phobia, Panic Disorder, Post Traumatic Stress (diagnosed using the SCID-5)\n* Written informed consent\n* For MDD subjects, a baseline Hamilton Depression Rating Scale score \\> 16 (17-item version)\n* Right-handed\n* Has a smartphone (iPhone or Android) (needed for Ecological Momentary Assessment)\n* Absence of any psychotropic medications for at least 2 weeks (6 weeks for fluoxetine, 6 months for neuroleptics, 2 weeks for benzodiazepines, 2 weeks for any other antidepressants)\n\nInclusion criteria for healthy controls:\n\n* Absence of medical, neurological, and psychiatric illness (including alcohol and substance abuse), as assessed by subject history and a structured clinical interview (diagnosed using the SCID-5)\n* Written informed consent\n* Right-handed\n* Absence of any medications for at least 3 weeks\n* Has a smartphone (iPhone or Android) (needed for Ecological Momentary Assessment)\n\nExclusion criteria for all participants:\n\n* Subjects with suicidal ideation where outpatient treatment is determined unsafe by the study clinician\n* Pregnant women or women of childbearing potential who are not using a medically accepted means of contraception\n* Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease\n* History of seizure disorder\n* History or current diagnosis of any of the following DSM-IV psychiatric illnesses: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, obsessive-compulsive disorder, patients with mood congruent or mood incongruent psychotic features, substance dependence, substance abuse within the last 12 months (with the exception of cocaine or stimulant abuse; which will lead to exclusion)\n* History of cocaine or stimulant use (e.g., amphetamine, cocaine, methamphetamine)\n* History of use of dopaminergic drugs (including methylphenidate)\n* History or current diagnosis of dementia\n* Patients with mood congruent or mood incongruent psychotic features\n* Current use of other psychotropic drugs\n* Clinical or laboratory evidence of hypothyroidism\n* Patients with a lifetime history of electroconvulsive therapy\n* Failure to meet standard magnetic resonance imaging safety requirements\n* Abnormal ECG and lab results\n* History of seizure disorder or currently on anticonvulsants","45 Years",{"count":76,"type":21},112,[78],"PHASE2","The study will investigate whether a nociceptin receptor antagonist will normalize neural and behavioral processes of approach\u002Favoidance decision-making in unmedicated individuals with major depressive disorder (MDD) and anxiety disorders. More specifically, the study aims to investigate dysregulation within (1) corticostriatal-midbrain circuitry and (2) nociceptin\u002Forphanin FQ peptide and the nociceptin receptor (NOPR).",[81,26],"Depressive Disorder, Major","2026-05-15",{"date":84,"type":32},"2026-05-18",{"date":86,"type":32},"2025-02-01",{"date":88,"type":21},"2027-03-31",{"name":90,"class":39},"Mclean Hospital",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":99,"maxAge":17,"enrollmentInfo":100,"targetDuration":4,"studyType":51,"phases":102,"briefSummary":103,"conditions":104,"keywords":119,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":66},"100587910","implementing-team-based-treatment-for-pediatric-anxiety-in-community-mental-health-settings-100587910","NCT06934525","Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings","Testing Delivery of Modalities in Community Health Settings: Developing Pathways to Health Equity","IMPACT-RI","Inclusion Criteria:\n\n* Age 5-18 inclusive\n* Primary or co-primary DSM-V diagnosis of anxiety or OCD\n* Symptom duration of at least 3 months\n* Outpatient care needed\n* Presence of a stable parent, or guardian, who can participate in treatment\n\nExclusion Criteria:\n\n* Other primary or co-primary psychiatric disorder which requires initiation of other active current treatment\n* Acute suicidality\n* Concurrent psychotherapy\n* Chronic medical illness that would preclude their active participation in treatment\n* Treatment with psychotropic medication that is not stable","5 Years",{"count":101,"type":21},501,[53],"The purpose of this study is to test how the delivery of Cognitive Behavioral Therapy (CBT) for pediatric anxiety and OCD via different methods might increase its availability and effectiveness. CBT involves teaching the patient skills to enable them to gradually come into contact with feared situations. This process of gradually approaching feared situations is called exposure. Although CBT with exposure has the best evidence for treating anxiety disorders, not all children have equal access or respond the same way to CBT. As part of this study, patients will receive weekly CBT treatment sessions involving a combination of weekly visits with an exposure coach and one visit a month with a licensed provider (e.g., psychologist, social worker). This treatment will be delivered using one of three methods: 1) in-person (face-to-face sessions, occurring in the office and the home\u002Fcommunity), or 2) telehealth (entirely remote sessions via web-based video conference), or 3) flexible (individualized mix of in-person and\u002For telehealth sessions). Eligible participants will be randomly assigned to one of these three methods. Results of this study will help determine which treatment method works best for whom.\n\nTreatment as described above will occur as part of care at partnering community care sites in Rhode Island. Providers from the following partnering community care sites will make up patient treatment teams: Blackstone Valley Community Health Care, Family Services of Rhode Island, Gateway Healthcare, Newport Mental Health, and Thrive Behavioral Health.\n\nThe research study is being conducted by the Pediatric Anxiety Research Center at Brown University Health. The research team will conduct the study assessments that patients will be asked to participate in as study participants. Patients will be asked to complete assessments prior to starting treatment, at two time points during treatment, at the end of treatment, and at two timepoints 3 and 6 months following the end of treatment. Participants will be compensated for their time completing research assessments.",[105,106,26,107,108,109,110,111,112,113,114,115,116,117,118],"Obsessive Compulsive Disorder (OCD)","Pediatric Anxiety Disorders","Anxiety","OCD","Phobia","Agoraphobia","Generalized Anxiety","Generalized Anxiety Disorder","Selective Mutism","Separation Anxiety","Social Anxiety","Social Anxiety Disorder","Panic Disorder","Pediatric Disorders",[120,121,122,123,124,125],"exposure therapy","cognitive behavioral therapy","anxiety treatment","exposure and response prevention therapy","ERP","pediatric anxiety treatment","2026-05-13",{"date":128,"type":32},"2026-05-14",{"date":130,"type":32},"2025-11-01",{"date":132,"type":21},"2029-08-01",{"name":134,"class":39},"Bradley Hospital",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":51,"phases":145,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":66},"100634707","right-dorsolateral-prefrontal-cortex-closed-loop-neurofeedback-for-anxiety-in-high-ischaemic-risk-chronic-coronary-syndrome-100634707","NCT07543185","Right Dorsolateral Prefrontal Cortex Closed-loop Neurofeedback for Anxiety in High-ischaemic-risk Chronic Coronary Syndrome","Right Dorsolateral Prefrontal Cortex Closed-loop Neurofeedback for Anxiety in High-ischaemic-risk Chronic Coronary Syndrome: a Randomized, Sham-controlled Trial","HEART-SET-3","Inclusion Criteria:\n\n* Participants will be aged 18 years or older and will provide written informed consent.\n* Participants will have chronic coronary syndrome (CCS) with prior coronary stent implantation more than 6 months before enrollment.\n* Participants will meet high ischemic risk (HIR) criteria by either of the following:\n\n  * Percutaneous coronary intervention (PCI) performed more than 6 months earlier for acute coronary syndrome (ACS), including unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction, with implantation of at least 1 coronary stent; or\n  * PCI performed more than 6 months earlier for a non-ACS indication, together with at least 1 of the following risk factors:\n\n    * diabetes mellitus;\n    * diffuse multivessel coronary artery disease involving all 3 major coronary vessels;\n    * chronic kidney disease with creatinine clearance less than 50 mL\u002Fmin (recommended to be calculated using the Cockcroft-Gault formula);\n    * prior stent thrombosis;\n    * peripheral arterial disease;\n    * complex PCI, defined by at least 1 of the following:\n\n      * only patent remaining coronary vessel or left main coronary artery stenting;\n      * implantation of at least 3 stents or treatment of at least 3 lesions;\n      * bifurcation lesion treated with a 2-stent strategy;\n      * total stent length greater than 60 mm;\n      * PCI for chronic total occlusion.\n* Participants will meet DSM-5 diagnostic criteria for an anxiety disorder, confirmed by structured psychiatric interview.\n* Participants will have a Hamilton Anxiety Rating Scale (HAMA) score of 16 or higher.\n* Participants will have a 17-item Hamilton Depression Rating Scale (HAMD-17) score lower than 17.\n* Participants will not have used psychotropic medication, including antidepressants, anxiolytics, or antipsychotics, within 1 month before enrollment; prior psychotropic medication use will not itself exclude participation, provided that a washout period has been completed before enrollment and the medication history is documented.\n\nExclusion Criteria:\n\n* Participants will be excluded if they have severe congestive heart failure (New York Heart Association class IV).\n* Participants will be excluded if they have moderate-to-severe valvular heart disease.\n* Participants will be excluded if they have a history of atrial fibrillation.\n* Participants will be excluded if they have unstable blood pressure, defined as systolic blood pressure greater than 180 mmHg or less than 90 mmHg.\n* Participants will be excluded if they are pregnant or breastfeeding.\n* Participants will be excluded if they have active or recent (within 6 months) severe systemic disease, including any of the following:\n\n  * cerebrovascular disease, including stroke or transient ischemic attack;\n  * dementia or severe cognitive impairment;\n  * hyperthyroidism;\n  * active pulmonary disease;\n  * active malignant tumor.\n* Participants will be excluded if they have suicidal or homicidal risk based on clinical interview.\n* Participants will be excluded if they have other severe psychiatric disorders, including but not limited to:\n\n  * psychotic disorders, such as hallucinations or delusions;\n  * bipolar disorder.",{"count":144,"type":21},214,[53],"This study is a prospective, randomized, sham-controlled, participant- and assessor-blinded, parallel-group clinical trial designed to evaluate the clinical efficacy, mechanistic effects, and safety of right dorsolateral prefrontal cortex (DLPFC) closed-loop functional near-infrared spectroscopy brain-computer interface (fNIRS-BCI) neurofeedback in patients with high-ischaemic-risk chronic coronary syndrome (CCS) and comorbid anxiety disorder. Participants will be randomly assigned in a 1:1 ratio to active neurofeedback or sham feedback. The intervention consists of 4 weeks of treatment, with 20 sessions in total (1 session per weekday, approximately 20 minutes per session). The primary endpoint is the between-group difference in Hamilton Anxiety Rating Scale (HAMA) score at 3 months after treatment. Secondary endpoints include HAMA score and HAMA response rate at the end of treatment, as well as neurophysiological measures collected during Session 1, including right DLPFC activation, heart rate (HR), and heart rate variability (HRV). Exploratory long-term follow-up will assess cardiovascular and bleeding outcomes through 4 years after randomization.",[148,26,149],"Chronic Coronary Syndrome","High Ischemic Risk",[151,152,153,154],"closed-loop neurofeedback","fNIRS-BCI","right dorsolateral prefrontal cortex","psycho-cardiology","NOT_YET_RECRUITING","2026-04-14",{"date":158,"type":32},"2026-04-21",{"date":160,"type":21},"2026-04-19",{"date":162,"type":21},"2031-02-20",{"name":164,"class":39},"Shenyang Medical College",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":51,"phases":175,"briefSummary":176,"conditions":177,"keywords":183,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":66},"100609963","virtual-reality-intervention-to-improve-psychological-symptom-burden-for-cancer-patients-undergoing-treatment-100609963","NCT07221409","Virtual Reality Intervention to Improve Psychological Symptom Burden for Cancer Patients Undergoing Treatment","Pilot Study to Assess Safety, Tolerability and Efficacy of Virtual Reality in Cancer Patients","Inclusion Criteria:\n\n* History of cancer\n* Age between 18 to 90 years\n* Undergoing in-patient chemotherapy, bone marrow transplant (BMT), chimeric antigen receptor (CAR)-t, \\& out-patient chemotherapy\n\nExclusion Criteria:\n\n* History of bipolar disorder, major depression, bipolar disorder, anxiety disorder, post traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD), psychotic disorder, schizophrenia, personality disorder, substance use disorder other than caffeine or tobacco. History of suicidal ideation or attempt\n* History of treatment resistant depression, psychiatric hospitalization, syncope, transient ischemic attack (TIA), stroke, epilepsy, electroconvulsive therapy, benign positional vertigo, Meniere's disease","90 Years",{"count":174,"type":21},24,[53],"This clinical trial tests the safety, tolerability, and effectiveness of a virtual reality intervention to improve psychological symptom burden for cancer patients undergoing treatment. Virtual reality (VR) is a technology that allows users to experience and interact with three-dimensional, computer-generated environments that simulate the real world or imagined settings. The VR intervention consists of a preloaded with immersive environments designed to engage the senses through simulated sights and sounds. This may include a walk through of a serene forest, exploring vibrant coral reefs, swimming with dolphins, or standing at the base of a majestic waterfall. These environments are created to provide a relaxing and engaging experience. Completing the VR intervention may be a safe and effective way to improve quality of life, reduce anxiety, enhance focus, and promote healthy living for cancer patients undergoing treatment.",[178,26,179,180,181,182],"Adjustment Disorder","Depression","Hematopoietic and Lymphoid System Neoplasm","Malignant Solid Neoplasm","Cancer",[184,185,186,187],"Virtual Reality Therapy","VR Therapy","Non-Pharmacologic Intervention","Cancer Supportive Care","2026-03-31",{"date":190,"type":32},"2026-04-02",{"date":192,"type":32},"2025-10-08",{"date":194,"type":21},"2027-10-08",{"name":196,"class":39},"Mayo Clinic",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":51,"phases":207,"briefSummary":208,"conditions":209,"keywords":214,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":66},"100623481","act-for-veterans-with-ibd-and-mental-health-challenges-100623481","NCT07397195","ACT for Veterans With IBD and Mental Health Challenges","Using Acceptance and Commitment Training to Promote Rehabilitation and Engagement in Values-Centered Living in Veterans Adapting to Inflammatory Bowel Disease and Mental Health Challenges (RECLAIM)","RECLAIM","Inclusion Criteria:\n\n* Diagnosis of IBD as confirmed by the medical record\n* Current diagnosis of a depressive, anxiety, or trauma-related disorder\n\nExclusion Criteria:\n\n* Severe IBD symptoms that would prevent full participation in the study (i.e., hospitalized in the past 30 days, surgery in the past 30 days)\n* Significant cognitive impairment\n* Active suicidality\n* Uncontrolled psychosis or bipolar disorder",{"count":206,"type":21},50,[53],"Many Veterans with gastrointestinal disorders, such as inflammatory bowel disease (IBD), also have mental health conditions. IBD and mental health conditions can worsen one another through the brain-gut axis, leading to dramatic deficits in psychosocial functioning and quality of life (QOL). Yet, few Veterans with comorbid IBD and mental health conditions receive psychotherapy and no evidence-based psychotherapies have been tested in Veterans with these comorbidities. Adapting brief acceptance and commitment therapy (ACT) to the specific to the needs of these patients and embedding treatment into routine gastroenterology care may increase Veterans' access to efficient and effective rehabilitative care. This study aims to adapt and test an integrated, 1-Day ACT intervention tailored to the specific needs of Veterans with IBD and mental health conditions to improve psychosocial functioning and QOL.",[210,211,212,56,26,213],"Inflammatory Bowel Diseases","Crohn's Disease","Ulcerative Colitis","Stress Disorders, Post-Traumatic",[215,216,210,217,56,213],"Acceptance and Commitment Therapy","Veterans","Anxiety Disorders","2026-02-02",{"date":220,"type":32},"2026-02-09",{"date":222,"type":21},"2028-01-01",{"date":224,"type":21},"2032-06-30",{"name":226,"class":227},"VA Office of Research and Development","FED",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":51,"phases":236,"briefSummary":237,"conditions":238,"keywords":240,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":66},"100604289","effect-of-transcranial-alternating-current-stimulation-on-sleep-disorder-and-anxiety-in-elderly-population-100604289","NCT07147582","Effect of Transcranial Alternating Current Stimulation on Sleep Disorder and Anxiety in Elderly Population","Inclusion Criteria:\n\n-healthy elderly adult aged more than 60 years old, both sex, and suffering from insomnia and sleep disorders\n\nExclusion Criteria:\n\n* neurological and vascular diseases.",{"count":235,"type":21},60,[53],"Sleep disorders and anxiety are complicated disorders affecting population especially elderly population, therefore treating these disorders will have positive impact on population production and quality of life.",[239,26],"Chronic Sleep Disorders",[107,241,242],"Elderly","Sleep Dsorders","2025-11-15",{"date":245,"type":32},"2025-11-18",{"date":247,"type":21},"2025-11",{"date":249,"type":21},"2026-02",{"name":251,"class":39},"Cairo University",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":259,"targetDuration":4,"studyType":51,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":272,"locationsCount":66},"100538927","low-intensity-focused-ultrasound-and-the-complex-patient-100538927","NCT06297200","Low-Intensity Focused Ultrasound and the Complex Patient","Investigations of Low-Intensity Focused Ultrasound Towards Treatment for the Complex Patient","Inclusion Criteria:\n\n1. Males and females aged 18-65 years\n2. Current diagnosis of Chronic Back Pain as defined by pain duration of at least three months, with back pain being an ongoing problem for at least half the days of the last six months.\n3. Have evidence of central sensitization (CS) as measured by the Widespread Pain\u002FSymptom Severity Index (WPSSI) with a score of Widespread Pain Index (WPI) ≥ 7 and Symptom Severity (SS) ≥ 5 or WPI = 3-6 and SS ≥ 9.\n4. Meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for current opiate use disorder as diagnosed by the Structured Clinical Interview for DSM-5.\n5. Be in treatment for opioid use disorder (OUD) including buprenorphine or methadone.\n6. Meet the DSM-5 criteria for a current anxiety disorder: generalized anxiety disorder, post-traumatic stress disorder or social anxiety disorder as diagnosed by the Structured Clinical Interview for DSM-5.\n\nExclusion Criteria:\n\n1. Evidence of neuropathic pain\n2. Previous spine surgery\n3. Current substance use disorder other than OUD or tobacco use disorder\n4. Current DSM-5 diagnosis of schizophrenia or schizo-affective disorder\n5. Chronic Pain Conditions other than chronic back pain\n6. Daily opiate use other than buprenorphine\u002Fmethadone for OUD\u002Fpain control\n7. Pregnant or breastfeeding\n8. History of head injury, seizures, neurologic disorders including cerebrovascular disease, stroke, brain surgery, brain tumor, multiple sclerosis, or neurodegenerative diseases\n9. History of metastasizing cancers, inflammatory disorder (rheumatoid arthritis, polymyalgia rheumatica, scleroderma, lupus or polymyositis), unintended weight loss of 20 pounds or more in the last year, or cauda equina syndrome\n10. Ferromagnetic implants or other contraindications for magnetic resonance imaging (MRI)\n11. Evidence of arteriovenous malformation, aneurysm, infarct, meningioma, parenchymal brain tumor or evidence of neurodegenerative processes and\u002For white matter lesions greater than that expected for age as determined by the study neuroradiologist\n12. Unstable medical conditions such as congestive heart failure, unstable angina, poorly controlled arrhythmia active system infection end stage renal disease",{"count":260,"type":21},25,[53],"Studying the effects of Low Intensity Focused Ultrasound (LIFU) on measures of pain, craving, and anxiety in a complex patient population.",[264,265,26],"Opioid Use Disorder","Chronic Pain","2025-10-31",{"date":268,"type":32},"2025-11-03",{"date":270,"type":32},"2024-12-04",{"date":63,"type":21},{"name":273,"class":39},"Virginia Polytechnic Institute and State University",{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":16,"minAge":280,"maxAge":281,"enrollmentInfo":282,"targetDuration":4,"studyType":51,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":66},"100519067","unified-protocol-community-connections-100519067","NCT06038721","Unified Protocol: Community Connections","Inclusion Criteria:\n\n* Children between the ages of 7-17.\n* Youth currently resides in Miami-Dade County.\n* Children and their parents must be able to speak and understand English and\u002For Spanish sufficiently well to complete study procedures (e.g., provide their informed consent\u002Fassent, complete assessment measures and\u002For program materials).\n* At least one parent or caregiver with whom the child is living with that can accompany the child and participate in all visits (assessment and treatment).\n* Positive endorsement of elevated emotional concerns in one of a limited range of emotional disorder domains (i.e., anxiety, depression, trauma, or obsessive-compulsive symptoms, etc.) during full DIAMOND-Kid semi-structured interview, and\u002For elevated anxiety or depression symptoms (T-Score \\> or = 65 for youth 8-17 years old; Raw score \\> or = 12 for children under 8 years old) on the Revised Child Anxiety and Depression Scale - Short Form (RCADS-SF; Child or Parent Report).\n* Youth with other types of comorbid conditions (e.g., tic\u002FTourette's disorder, eating disorders, or disruptive behavior disorders) will not be excluded, providing a clinical area of concern is regarding one of the emotional disorder domains specified and treatment within this protocol is deemed most appropriate.\n* Youth and parent participation in at least one in-person session if the treatment is predominantly delivered virtually.\n\nExclusion Criteria:\n\n* Prior receipt of at least 8 sessions of the UP-C\u002FA program at the Child and Adolescent Mood and Anxiety Treatment Program (CAMAT).\n* Psychiatric hospitalization in the previous 6 months (i.e., due to Baker Act, psychotic symptoms, significant suicidal ideation, danger to self or others, etc.).\n* Another significant problem area that takes priority for services (e.g., eating disorder, substance-use disorder, primary externalizing concerns, psychotic symptoms, etc.), as identified by family report or via DIAMOND-Kid interview.\n* Inability for family to wait for the next group treatment cohort to start, family declining therapist assignment following intake, and\u002For family no-showing to 3 or more scheduled sessions at CAMAT (inclusive of intake assessment).","7 Years","17 Years",{"count":283,"type":21},1500,[53],"The purpose of this study is to administer the Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children (UP-C) and Adolescents (UP-A) to youth and participants' parents and to examine the efficacy and outcomes of the treatment using standardized measures, questionnaires, interviews. The UP-C and the UP-A are cognitive-behavioral therapies to treat emotional disorders.",[287,26,56,288],"Mental Health Issue","Parenting","2025-09-09",{"date":291,"type":32},"2025-09-11",{"date":293,"type":32},"2023-09-25",{"date":295,"type":21},"2028-09-25",{"name":297,"class":39},"University of Miami",{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":306,"targetDuration":4,"studyType":51,"phases":308,"briefSummary":309,"conditions":310,"keywords":312,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":66},"100469492","electroclinical-correlation-of-anxiety-100469492","NCT05393518","Electroclinical Correlation of Anxiety","Electroclinical Correlation of Anxiety, Evidences From Intracerebral Recordings","IRAnxNet","Inclusion Criteria:\n\n* Man or woman\n* Aged 18 to 65;\n* With drug-resistant epilepsy\n* Benefiting from a phase II pre-surgical assessment with intracerebral electrophysiological exploration by stereo-EEG\n* Meeting the DSM-5 diagnostic criteria for generalized anxiety disorder (\"pathological\" population) or not meeting the DSM-5 diagnostic criteria for generalized anxiety disorder (\"control\" population)\n* WAIS IV full scale IQ \\> 75 or IAG \\> 81\n* Affiliate or beneficiary of a social security scheme\n* Giving free, informed consent in writing and signed by the participant and the investigator\n\nExclusion Criteria:\n\n* Being unable to give personal consent\n* Be subject to a measure of legal protection (curatorship, guardianship) or placed under judicial protection;\n* Suffer from a chronic delusional disorder (eg: schizophrenia);\n* Have a moderate or high risk of suicide assessed using the corresponding section of the structured psychiatric interview called \"Mini International Neuropsychiatric Interview\" (M.I.N.I. 7.0) or a score \\> 2 on item 10 of the MADRS, assessing suicidal risk;\n* Being pregnant or breastfeeding\n* Have severe and \u002F or decompensated somatic illness other than drug-resistant epilepsy",{"count":307,"type":21},30,[53],"Anxiety disorders have the highest prevalence among mental disorders and cause considerable individual and financial costs. Current treatments do not relieve mental suffering of many patients. Understanding neurobiological mechanisms involved in pathological anxiety is a major scientific challenge.",[26,112,311],"Drug Resistant Epilepsy",[313,112,314,315,316,317],"Focal epilepsy","Intracranial recordings","Stereoenectroencephalography","Coherence","Networks","2025-07-22",{"date":320,"type":32},"2025-07-25",{"date":322,"type":32},"2022-10-11",{"date":324,"type":21},"2026-10-11",{"name":326,"class":39},"University Hospital, Bordeaux",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":15,"sex":334,"minAge":17,"maxAge":74,"enrollmentInfo":335,"targetDuration":4,"studyType":51,"phases":337,"briefSummary":338,"conditions":339,"keywords":342,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":357},"100589332","effects-of-acupressure-applied-before-cesarean-delivery-on-anxiety-physiological-parameters-and-fetal-heart-rate-100589332","NCT06953037","Effects of Acupressure Applied Before Cesarean Delivery on Anxiety, Physiological Parameters and Fetal Heart Rate","Effects of Acupressure Applied Before Cesarean Delivery on Anxiety, Physiological Parameters and Fetal Heart Rate: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Agree to participate in the study,\n* Be between the ages of 18-45,\n* Have a caesarean section between 37-40 weeks,\n* Not have a risky pregnancy,\n* Have spinal anesthesia,\n\nExclusion Criteria:\n\n* Not having anxiety 1 hour before the cesarean section,\n* Having a risky pregnancy,\n* Having a chronic disease,\n* Having a severe systemic disease,\n* Not receiving spinal anesthesia,\n* Having a body mass index over 25,\n* Having previous acupressure experience,","FEMALE",{"count":336,"type":21},64,[53],"Cesarean section is the most commonly preferred surgical method in cases where vaginal birth is not possible or complications that may endanger the health of the mother and baby occur. Cesarean section rates are increasing worldwide. According to the latest data (2010-2018) from 154 countries covering 94.5% of live births in the world, 21.1% of women have cesarean section births and it is estimated that this rate will increase to 28.5% by 2030. According to the Centers for Disease Control and Prevention (CDC), the cesarean section rate in the USA, which was 32.1% in 2022, increased to 32.4% in 2023. When the cesarean section rates of the Turkey Demographic Health Survey (TDHS) are examined, the rate, which was 7% in 1993, increased to 52% in 2018, an increase of 45% is observed. In the TRNC, this rate was 11.1% in 1981, but in 2017 this rate increased by an average of 7 times, reaching 72.5%. Pregnant women tend to have cesarean sections because they are affected by the risks that will occur during birth, negative birth stories told among the public, and painful birth scenes seen on social media. Studies have shown that despite the high rates of cesarean sections in pregnant women's birth methods, a significant increase in women's anxiety levels is observed. While waiting for the surgery, pre-operative anxiety, fear of the procedure, etc. are more common than other feelings and symptoms.Studies have also shown that anxiety increases in patient rooms, the night before surgery, and when moving to the operating table. In a study conducted by Lopez, the most important causes of preoperative anxiety were listed as fear of the hospital environment (35%), fear of surgery (33%), fear of anesthesia (45%), and unawareness of the surgery (45%). Concerns about the success of the operation (29.3%), fear of postoperative prognosis (19.5%), and surgical complications (11.4%) are the most common causes of preoperative anxiety. High levels of anxiety experienced before surgery cause increased heart rate, blood pressure, and oxygen consumption during surgery.\n\nControlling and managing preoperative anxiety is one of the most important goals of nursing care worldwide, as in cesarean cases. Mothers need to relax mentally and physically after cesarean sections so that they can care for their babies after birth. A common way to control preoperative anxiety is to use sedatives, but these medications can cause side effects. Therefore, acupressure, which is a non-invasive, low-cost, uncomplicated and non-pharmacological method due to fewer complications, can be used to reduce preoperative anxiety. Acupressure is the application of pressure to stimulate acupoints and meridian lines using an object or fingers, without the use of needles. Acupressure is a simple treatment approach and can be applied by nurses or patients who have received the necessary training, because it is simple and does not require any equipment.",[340,341,26],"Caesarean Section","Pregnant Women",[343,344,345,346,347],"pregnant women","caesarean section","anxiety","fetal heart rate","accupressure","2025-04-29",{"date":350,"type":32},"2025-05-01",{"date":352,"type":21},"2025-05-15",{"date":354,"type":21},"2025-07-05",{"name":356,"class":39},"Eastern Mediterranean University",2,{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":51,"phases":368,"briefSummary":369,"conditions":370,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":66},"100303029","courageous-parents-courageous-children-100303029","NCT03224845","Courageous Parents, Courageous Children","Transgenerational Prevention of Anxiety in Children at Ultra-high Risk","COACH","Parents:\n\nInclusion criteria:\n\nParents will be included if they have a current diagnosis of at least one anxiety disorder, one or more children between the ages two and eight years in their own care, capacity to provide informed consent, and ability to speak English well enough to benefit from the intervention.\n\nExclusion criteria:\n\nExclusion criteria for parents are receipt of an adequate course (6 or more sessions) of structured psychological therapy in the past 12 months, or plans to move out of Nova Scotia within the next three years. We will include parents with co-morbid mood disorders. However, those whose mood disorder is the primary complaint will be referred for treatment for their mood before being re-assessed. We will exclude parents with disorders that would interfere with the standard treatment protocol delivery; these include lifetime schizophrenia, autism, intellectual disability and current drug and alcohol use disorder.\n\nOffspring:\n\nInclusion criteria:\n\nChildren are eligible if they are aged two to eight and if they have a score of inhibited temperament (negative emotionality) one standard deviation or more above the mean of an age-matched normative sample on the Laboratory Assessment of Temperament.\n\nExclusion criteria:\n\nThose with lifetime schizophrenia, autism, general intellectual disability, and current drug and alcohol addiction will be excluded, as these conditions would impact on the standard delivery of the parenting intervention. We will exclude children currently receiving treatment for anxiety.",{"count":367,"type":21},88,[53],"Anxiety disorders usually start in childhood and adolescence and are associated with social and occupational difficulties in adulthood. Children who have a parent with an anxiety disorder and who find new situations distressing and avoid them are at an increased risk for developing an anxiety disorder. Research suggests that anti-anxiety parenting can help children grow up courageous and calm. It is, however, difficult to parent in an anti-anxiety way when the parent has an anxiety disorder himself or herself.\n\nThis research study will test the efficacy of a new program designed to prevent the onset or persistence of anxiety disorders in children at risk for anxiety disorders. The investigators will first help parents learn skills to cope with their own anxiety and then coach them to share these skills with their children and parent in an anti-anxiety way. The goal is to intervene early enough in the children's lives so that they can be free of anxiety disorders and lead happy, healthy and productive lives in adulthood.",[26],"2024-08-19",{"date":373,"type":32},"2024-08-21",{"date":375,"type":32},"2017-09-17",{"date":377,"type":21},"2025-09",{"name":379,"class":39},"Nova Scotia Health Authority",{"id":381,"slug":382,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":388,"targetDuration":4,"studyType":51,"phases":390,"briefSummary":391,"conditions":392,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":66},"100555861","process-based-therapy-for-difficult-to-treat-anxiety-disorders-and-depression-100555861","NCT06517589","Process-based Therapy for Difficult-to-treat Anxiety Disorders and Depression","Process-based Therapy vs. Routine-CBT for Difficult-to-treat Anxiety Disorders and Depression","PBTRAND","Inclusion Criteria:\n\n* A primary DSM-5 diagnosis of depressive or anxiety disorder\n* At least two unsuccessful attempts of pharmacological or psychological treatment according to the German guidelines for the treatment of depression or anxiety disorders (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF)\n* Age 18-65 years\n* Sufficient knowledge of the German language\n* Participating patients are not required to discontinue medication, but to keep medication constant over the treatment period\n\nExclusion Criteria:\n\n* Increased suicidality\n* Substance abuse or dependency\n* Borderline personality disorder\n* Pervasive developmental disorder\n* Psychotic disorder\n* Eating disorder\n* Bipolar disorder\n* Severe physical illness",{"count":389,"type":21},80,[53],"The aim of this study is to test the relative efficacy of Process-based Therapy compared to traditional CBT delivered in routine practice (r-CBT) for difficult-to-treat anxiety disorders and depression.",[179,26],"2024-07-28",{"date":395,"type":32},"2024-07-30",{"date":397,"type":32},"2024-01-29",{"date":399,"type":21},"2025-07-30",{"name":401,"class":39},"Goethe University",{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":411,"conditions":412,"keywords":413,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":66},"100528038","understanding-patient-engagement-trends-in-anxiety-disorder-clinical-research-100528038","NCT06155565","Understanding Patient Engagement Trends in Anxiety Disorder Clinical Research","Investigating Patterns in Enrollment and Engagement Among Individuals Coping With Anxiety Disorder","Inclusion Criteria:\n\n* Aged ≥ 18 years old\n* Diagnosis of anxiety disorder\n* Able to comprehend the investigational nature of the protocol and provide informed consent\n\nExclusion Criteria:\n\n* Female patients who are currently pregnant or nursing\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Inability to perform regular electronic reporting",{"count":410,"type":21},500,"Clinical trials, specifically focused on anxiety disorder, are crucial in assessing the safety and efficacy of new treatments. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation.\n\nThe main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.",[26],[414],"anxiety disorder","2023-11-24",{"date":417,"type":32},"2023-12-04",{"date":419,"type":21},"2024-12",{"date":421,"type":21},"2026-12",{"name":423,"class":424},"Power Life Sciences Inc.","INDUSTRY"]